Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APL-10456-Vaccine in Healthy Volunteers
NCT07399132Phase 1Active, not recruiting
- Sponsor
- Apollo Therapeutics
- Start
- Feb 2026
- Primary completion
- May 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of APL-10456 in rhinovirus infection (2 arms), sponsored by Apollo Therapeutics. Primary endpoint: Safety and Reactogenicity at 365 days. Started Feb 2026; status: active, not recruiting.
02
Drugs
APL-10456
03
Conditions
rhinovirus infection
Beyond the preview
Go deeper on NCT07399132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07399132.